Literature DB >> 30942440

Tumor‑suppressive microRNA‑223 targets WDR62 directly in bladder cancer.

Satoshi Sugita1, Hirofumi Yoshino1, Masaya Yonemori1, Kazutaka Miyamoto1, Ryosuke Matsushita1, Takashi Sakaguchi1, Toshihiko Itesako1, Shuichi Tatarano1, Masayuki Nakagawa1, Hideki Enokida1.   

Abstract

miRNA‑223 (miR‑223) has been reported to function not only as a tumor suppressor, but also as an oncogenic microRNA (miRNA or miR) in various cancer cells. Therefore, the functional role of miR‑223 has not been elucidated to date, at least to the best of our knowledge. We previously performed the deep sequencing analysis of clinical bladder cancer (BC) specimens. It was revealed that miR‑223 expression was significantly downregulated in BC, suggesting that miR‑223 functions as a tumor suppressor miRNA in BC. The aim of this study was to investigate the functional roles of miR‑223 and to identify its targets in BC. The expression levels of miR‑223 were significantly decreased in our clinical BC specimens. The Cancer Genome Atlas (TCGA) database indicated that miR‑223 expression was related to lymphovascular invasion and distant metastasis. The restoration of miR‑223 expression significantly inhibited tumor aggressiveness and induced apoptosis via caspase‑3/7 activation in BC cells. WD repeat domain 62 (WDR62), a candidate target of miR‑223 according to in silico analyses, has been previously proposed to play a role in neurodevelopment. Direct binding between WDR62 and miR‑223 was confirmed by luciferase assay. The TCGA database revealed positive associations between WDR62 mRNA expression and a higher tumor grade and stage in BC. The knockdown of WDR62 significantly inhibited tumor aggressiveness and induced the apoptosis of BC cells. On the whole, the findings of this study reveal a novel miR‑223 target, oncogenic WDR62, and provided insight into the oncogenesis of BC.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30942440     DOI: 10.3892/ijo.2019.4762

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  11 in total

1.  Multi-view Co-training for microRNA Prediction.

Authors:  Mohsen Sheikh Hassani; James R Green
Journal:  Sci Rep       Date:  2019-07-29       Impact factor: 4.379

2.  Long noncoding RNA NNT-AS1 enhances the malignant phenotype of bladder cancer by acting as a competing endogenous RNA on microRNA-496 thereby increasing HMGB1 expression.

Authors:  Deyao Wu; Tielong Zhang; Jie Wang; Jian Zhou; Huixing Pan; Ping Qu
Journal:  Aging (Albany NY)       Date:  2019-12-17       Impact factor: 5.682

3.  EHHADH contributes to cisplatin resistance through regulation by tumor-suppressive microRNAs in bladder cancer.

Authors:  Shunsuke Okamura; Hirofumi Yoshino; Kazuki Kuroshima; Masafumi Tsuruda; Yoichi Osako; Takashi Sakaguchi; Masaya Yonemori; Yasutoshi Yamada; Shuichi Tatarano; Masayuki Nakagawa; Hideki Enokida
Journal:  BMC Cancer       Date:  2021-01-11       Impact factor: 4.430

Review 4.  Emerging Biomarkers for Predicting Bladder Cancer Lymph Node Metastasis.

Authors:  Chunyu Zhang; Jiao Hu; Huihuang Li; Hongzhi Ma; Belaydi Othmane; Wenbiao Ren; Zhenglin Yi; Dongxu Qiu; Zhenyu Ou; Jinbo Chen; Xiongbing Zu
Journal:  Front Oncol       Date:  2021-03-19       Impact factor: 6.244

5.  High Expression of microRNA-223 Indicates a Good Prognosis in Triple-Negative Breast Cancer.

Authors:  Li Chen; Xiuzhi Zhu; Boyue Han; Lei Ji; Ling Yao; Zhonghua Wang
Journal:  Front Oncol       Date:  2021-04-13       Impact factor: 6.244

6.  microRNA-99a-5p induces cellular senescence in gemcitabine-resistant bladder cancer by targeting SMARCD1.

Authors:  Motoki Tamai; Shuichi Tatarano; Shunsuke Okamura; Wataru Fukumoto; Issei Kawakami; Yoichi Osako; Takashi Sakaguchi; Satoshi Sugita; Masaya Yonemori; Yasutoshi Yamada; Masayuki Nakagawa; Hideki Enokida; Hirofumi Yoshino
Journal:  Mol Oncol       Date:  2022-02-28       Impact factor: 6.603

7.  Magnesium isoglycyrrhizinate suppresses bladder cancer progression by modulating the miR-26b/Nox4 axis.

Authors:  Zhihao Yuan; Guancheng Guo; Guifang Sun; Qi Li; Lihui Wang; Baoping Qiao
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

8.  WD repeat domain 62 (WDR62) promotes resistance of colorectal cancer to oxaliplatin through modulating mitogen-activated protein kinase (MAPK) signaling.

Authors:  Juanjuan Cai; Lingling Su; Weiwei Luo
Journal:  Bioengineered       Date:  2022-06       Impact factor: 6.832

9.  Systematic Analysis of the Oncogenic Role of WDR62 in Human Tumors.

Authors:  Yulan Bu; Lihua Zhang; Xiaolin Ma; Rui Wang; Xuecheng Zhang; Jiaqiu Li
Journal:  Dis Markers       Date:  2021-07-01       Impact factor: 3.434

10.  Comprehensive Analysis of Correlations in the Expression of miRNA Genes and Immune Checkpoint Genes in Bladder Cancer Cells.

Authors:  Przemysław A Stempor; Dror Avni; Raya Leibowitz; Yechezkel Sidi; Maria Stępień; Tomasz Dzieciątkowski; Paula Dobosz
Journal:  Int J Mol Sci       Date:  2021-03-04       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.